Page 1

SPAGO NANOMEDICAL AB Interim report January- June , 2021 Continued good pace in the business despite Covid - 19 APRIL - JUNE IN BRIEF ● ● JANUARY - JUNE IN BRIEF ● Net sales for the quarter amounted to KSEK 267 ( KSEK 0 ) . The loss for the quarter amounted to KSEK -11,607 ( KSEK -4,764 ) . Operating expenses for the quarter amounted to KSEK -13,450 ( KSEK -6,269 ) . Earnings per share , before and after dilution , for the quarter amounted to SEK -0.28 ( SEK -0.19 ) . Cash and cash equivalents at the end of the quarter amounted to KSEK 76 873 ( KSEK 41,421 ) . ● Net sales for the half - year period amounted to KSEK 367 ( KSEK 100 ) . The loss for the half - year period amounted to KSEK -17,675 ( KSEK -9,819 ) . Operating expenses for the half - year period amounted to KSEK -20,889 ( KSEK -13,039 ) . Earnings per share , before and after dilution , for the half - year period amounted to SEK -0.47 ( SEK -0.43 ) . SIGNIFICANT EVENTS DURING THE QUARTER No events to report SIGNIFICANT EVENTS AFTER THE QUARTER Paul Hargreaves was appointed Chief Development Officer ( CDO ) , starting in the third quarter . Paul will join the management team and have a key role in the clinical development of the company's project portfolio . Spago Nanomedical AB ( org . no . 556574-5048 ) – Interim report January - June 2021 spago NANOMEDICAL